These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33168224)

  • 1. Impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on acute mastoiditis in children in southern Israel: A 12-year retrospective comparative study (2005-2016).
    Sapir A; Ziv O; Leibovitz E; Kordeluk S; Rinott E; El-Saied S; Greenberg D; Kaplan DM
    Int J Pediatr Otorhinolaryngol; 2021 Jan; 140():110485. PubMed ID: 33168224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the epidemiology and clinical features of acute mastoiditis following the introduction of the pneumococcal conjugate vaccine.
    Cavel O; Tauman R; Simsolo E; Yafit D; Reindorf-Kfir E; Wasserzug O; Unger O; Handzel O; Fishman G; Oestreicher-Kedem Y; DeRowe A
    Int J Pediatr Otorhinolaryngol; 2018 Jan; 104():54-57. PubMed ID: 29287882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pneumococcal conjugate vaccines on incidence and microbiology associated with complicated acute otitis media.
    Laursen BB; Danstrup CS; Hoffmann S; Nørskov-Lauritsen N; Christensen ALB; Ovesen T
    Int J Pediatr Otorhinolaryngol; 2017 Oct; 101():249-253. PubMed ID: 28964304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal Mastoiditis in Children Before and After the Introduction of Conjugate Pneumococcal Vaccines.
    Koutouzis EI; Michos A; Koutouzi FI; Chatzichristou P; Parpounas K; Georgaki A; Theodoridou M; Tsakris A; Syriopoulou VP
    Pediatr Infect Dis J; 2016 Mar; 35(3):292-6. PubMed ID: 26569193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute mastoiditis in children under 15 years of age in Southern Israel following the introduction of pneumococcal conjugate vaccines: a 4-year retrospective study (2009-2012).
    Kordeluk S; Orgad R; Kraus M; Puterman M; Kaplan DM; Novak L; Dagan R; Leibovitz E
    Int J Pediatr Otorhinolaryngol; 2014 Oct; 78(10):1599-604. PubMed ID: 25074345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era.
    Kaplan SL; Center KJ; Barson WJ; Ling-Lin P; Romero JR; Bradley JS; Tan TQ; Hoffman JA; Peters TR; Gurtman A; Scott DA; Trammel J; Gruber WC; Hulten KG; Mason EO
    Clin Infect Dis; 2015 May; 60(9):1339-45. PubMed ID: 25648240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiologic and Microbiologic Characteristics of Occult Bacteremia Among Febrile Children in Southern Israel, Before and After Initiation of the Routine Antipneumococcal Immunization (2005-2012).
    Ribitzky-Eisner H; Minuhin Y; Greenberg D; Greenberg N; Chodick G; Craiu M; Leibovitz E
    Pediatr Neonatol; 2016 Oct; 57(5):378-384. PubMed ID: 26738763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children <2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation.
    Dagan R; Ben-Shimol S; Greenberg D; Givon-Lavi N
    Clin Infect Dis; 2021 Apr; 72(7):1200-1207. PubMed ID: 32140705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
    Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
    Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia.
    Desai AP; Sharma D; Crispell EK; Baughman W; Thomas S; Tunali A; Sherwood L; Zmitrovich A; Jerris R; Satola SW; Beall B; Moore MR; Jain S; Farley MM
    Pediatr Infect Dis J; 2015 Nov; 34(11):1168-74. PubMed ID: 26226445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
    Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD
    Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.
    Kaplan SL; Barson WJ; Lin PL; Romero JR; Bradley JS; Tan TQ; Hoffman JA; Givner LB; Mason EO
    Pediatr Infect Dis J; 2013 Mar; 32(3):203-7. PubMed ID: 23558320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.